• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

2021 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guideline: Management of castration-resistant prostate cancer (CRPC).

作者信息

Saad Fred, Aprikian Armen, Finelli Antonio, Fleshner Neil E, Gleave Martin, Kapoor Anil, Niazi Tamim, North Scott A, Pouliot Frederic, Rendon Ricardo A, Shayegan Bobby, Sridhar Srikala S, So Alan, Usmani Nawaid, Vigneault Eric, Chi Kim N

机构信息

Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada.

McGill University Health Center, Montreal, QC, Canada.

出版信息

Can Urol Assoc J. 2021 Feb;15(2):E81-E90. doi: 10.5489/cuaj.7074.

DOI:10.5489/cuaj.7074
PMID:33556313
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7864710/
Abstract
摘要

相似文献

1
2021 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guideline: Management of castration-resistant prostate cancer (CRPC).2021年加拿大泌尿外科学会（CUA）-加拿大泌尿肿瘤学组（CUOG）指南：去势抵抗性前列腺癌（CRPC）的管理
Can Urol Assoc J. 2021 Feb;15(2):E81-E90. doi: 10.5489/cuaj.7074.
2
2019 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guideline: Management of castration-resistant prostate cancer (CRPC).2019年加拿大泌尿外科学会（CUA）-加拿大泌尿肿瘤学组（CUOG）指南：去势抵抗性前列腺癌（CRPC）的管理
Can Urol Assoc J. 2019 Oct;13(10):307-314. doi: 10.5489/cuaj.6136.
3
2022 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guideline: Management of castration-resistant prostate cancer (CRPC).2022年加拿大泌尿外科学会（CUA）-加拿大泌尿肿瘤学组（CUOG）指南：去势抵抗性前列腺癌（CRPC）的管理
Can Urol Assoc J. 2022 Nov;16(11):E506-E515. doi: 10.5489/cuaj.8161.
4
UPDATE - 2021 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) castration-resistant prostate cancer (CRPC) guideline: What has changed since 2019?更新 - 2021年加拿大泌尿外科协会（CUA）-加拿大泌尿肿瘤学组（CUOG）去势抵抗性前列腺癌（CRPC）指南：自2019年以来有哪些变化？
Can Urol Assoc J. 2021 Feb;15(2):11-12. doi: 10.5489/cuaj.7160.
5
A Systematic Review of Clinical Practice Guidelines for Castration-Resistant Prostate Cancer.去势抵抗性前列腺癌临床实践指南的系统评价
Iran J Pharm Res. 2018 Winter;17(Suppl):17-37.
6
CUA-CUOG guidelines for the management of castration-resistant prostate cancer (CRPC): 2013 update.加拿大泌尿外科协会-加拿大泌尿外科肿瘤学组去势抵抗性前列腺癌（CRPC）管理指南：2013年更新版
Can Urol Assoc J. 2013 Jul-Aug;7(7-8):231-7. doi: 10.5489/cuaj.1542.
7
The 2015 CUA-CUOG Guidelines for the management of castration-resistant prostate cancer (CRPC).2015年加拿大泌尿外科协会-加拿大泌尿外科肿瘤学组去势抵抗性前列腺癌（CRPC）管理指南。
Can Urol Assoc J. 2015 Mar-Apr;9(3-4):90-6. doi: 10.5489/cuaj.2526.
8
Recommendations for the improvement of bladder cancer quality of care in Canada: A consensus document reviewed and endorsed by Bladder Cancer Canada (BCC), Canadian Urologic Oncology Group (CUOG), and Canadian Urological Association (CUA), December 2015.加拿大膀胱癌医疗质量改善建议：一份由加拿大膀胱癌协会（BCC）、加拿大泌尿外科肿瘤学组（CUOG）和加拿大泌尿外科协会（CUA）于2015年12月审核并认可的共识文件。
Can Urol Assoc J. 2016 Jan-Feb;10(1-2):E46-80. doi: 10.5489/cuaj.3583. Epub 2016 Feb 8.
9
Improving patient journey and quality of care: Summary from the second Bladder Cancer Canada-Canadian Urological Association-Canadian Urologic Oncology Group (BCC-CUA-CUOG) bladder cancer quality of care consensus meeting.改善患者就医流程与医疗质量：加拿大膀胱癌-加拿大泌尿外科协会-加拿大泌尿肿瘤学组（BCC-CUA-CUOG）第二届膀胱癌医疗质量共识会议总结
Can Urol Assoc J. 2018 Jul;12(7):E281-E297. doi: 10.5489/cuaj.5246. Epub 2018 Mar 19.
10
Continuing towards optimization of bladder cancer care in Canada: Summary of the third Bladder Cancer Canada-Canadian Urological Association-Canadian Urologic Oncology Group (BCC-CUA-CUOG) bladder cancer quality of care consensus meeting.加拿大膀胱癌护理持续优化：第三届加拿大膀胱癌-加拿大泌尿外科学会-加拿大泌尿肿瘤学组（BCC-CUA-CUOG）膀胱癌护理质量共识会议总结
Can Urol Assoc J. 2020 Mar;14(3):E115-E125. doi: 10.5489/cuaj.6378. Epub 2020 Feb 3.

引用本文的文献

1
Multicenter, international, retrospective study of prognostic factors for Ra223.镭-223预后因素的多中心、国际性回顾性研究。
Sci Rep. 2025 Mar 28;15(1):10814. doi: 10.1038/s41598-025-95844-8.
2
Prostate cancer management in Southeast Asian countries: a survey of clinical practice patterns.东南亚国家的前列腺癌管理：临床实践模式调查
Ther Adv Med Oncol. 2024 Jan 18;16:17588359231216582. doi: 10.1177/17588359231216582. eCollection 2024.
3
BeTTer Outcomes Workgroup Health Quality Initiative to optimize bone health for prostate cancer patients in the British Columbia Cancer System.更好结果工作组健康质量倡议，旨在优化不列颠哥伦比亚癌症系统中前列腺癌患者的骨骼健康。
Can Urol Assoc J. 2023 Aug 31;17(12):379-87. doi: 10.5489/cuaj.8477.
4
Genetic testing practices among specialist physicians who treat prostate cancer A Canadian, cross-sectional survey.治疗前列腺癌的专科医生的基因检测实践：一项加拿大横断面调查。
Can Urol Assoc J. 2023 Oct;17(10):326-336. doi: 10.5489/cuaj.8403.
5
Gender bias in shared decision-making among cancer care guidelines: A systematic review.癌症护理指南中共享决策制定的性别偏见：系统评价。
Health Expect. 2023 Jun;26(3):1019-1038. doi: 10.1111/hex.13753. Epub 2023 Apr 5.
6
HOW TO OPTIMALLY SEQUENCE AVAILABLE THERAPY LINES IN ADVANCED PROSTATE CANCER.如何在晚期前列腺癌中最优地排列可用的治疗线。
Acta Clin Croat. 2022 Oct;61(Suppl 3):32-44. doi: 10.20471/acc.2022.61.s3.5.
7
UPDATE - Canadian Urological Association guideline on androgen deprivation therapy: Adverse events and management strategies.更新——加拿大泌尿外科协会雄激素剥夺治疗指南：不良事件与管理策略
Can Urol Assoc J. 2022 Aug;16(8):E416-E431. doi: 10.5489/cuaj.8054.
8
The Health Economics of Metastatic Hormone-Sensitive and Non-Metastatic Castration-Resistant Prostate Cancer-A Systematic Literature Review with Application to the Canadian Context.转移性激素敏感和非转移性去势抵抗性前列腺癌的卫生经济学：系统文献回顾及其在加拿大背景下的应用。
Curr Oncol. 2022 May 7;29(5):3393-3424. doi: 10.3390/curroncol29050275.
9
Patients with Positive Lymph Nodes after Radical Prostatectomy and Pelvic Lymphadenectomy-Do We Know the Proper Way of Management?根治性前列腺切除术和盆腔淋巴结清扫术后淋巴结阳性的患者——我们知道正确的处理方法吗？
Cancers (Basel). 2022 May 8;14(9):2326. doi: 10.3390/cancers14092326.
10
Real-world experience of abiraterone acetate plus prednisone in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: long-term results of the prospective ABItude study.转移性去势抵抗性前列腺癌化疗初治患者中醋酸阿比特龙联合泼尼松的真实世界经验：前瞻性 ABItude 研究的长期结果。
ESMO Open. 2022 Apr;7(2):100431. doi: 10.1016/j.esmoop.2022.100431. Epub 2022 Apr 8.

本文引用的文献

1
Apalutamide and Overall Survival in Prostate Cancer.阿帕鲁胺与前列腺癌的总生存
Eur Urol. 2021 Jan;79(1):150-158. doi: 10.1016/j.eururo.2020.08.011. Epub 2020 Sep 6.
2
Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide.非转移性去势抵抗性前列腺癌和达罗他胺的生存情况。
N Engl J Med. 2020 Sep 10;383(11):1040-1049. doi: 10.1056/NEJMoa2001342.
3
Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer.恩扎卢胺与非转移性去势抵抗性前列腺癌的生存。
N Engl J Med. 2020 Jun 4;382(23):2197-2206. doi: 10.1056/NEJMoa2003892. Epub 2020 May 29.
4
Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trial.在非转移性去势抵抗性前列腺癌（PROSPER）男性中，恩扎卢胺或安慰剂治疗后的患者报告结局：一项多中心、随机、双盲、III 期临床试验。
Lancet Oncol. 2019 Apr;20(4):556-569. doi: 10.1016/S1470-2045(18)30898-2. Epub 2019 Feb 12.
5
Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial.镭-223 联合醋酸阿比特龙和泼尼松或泼尼松龙治疗去势抵抗性前列腺癌和骨转移患者（ERA 223）：一项随机、双盲、安慰剂对照、III 期临床试验。
Lancet Oncol. 2019 Mar;20(3):408-419. doi: 10.1016/S1470-2045(18)30860-X. Epub 2019 Feb 6.
6
Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial.阿帕鲁胺对非转移性去势抵抗性前列腺癌患者健康相关生活质量的影响：SPARTAN 随机、安慰剂对照、3 期临床试验分析。
Lancet Oncol. 2018 Oct;19(10):1404-1416. doi: 10.1016/S1470-2045(18)30456-X. Epub 2018 Sep 10.
7
Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer.恩杂鲁胺治疗去势抵抗性前列腺癌非转移性患者的疗效。
N Engl J Med. 2018 Jun 28;378(26):2465-2474. doi: 10.1056/NEJMoa1800536.
8
Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer.阿帕鲁胺治疗与前列腺癌无转移生存。
N Engl J Med. 2018 Apr 12;378(15):1408-1418. doi: 10.1056/NEJMoa1715546. Epub 2018 Feb 8.
9
Phase III Study Comparing a Reduced Dose of Cabazitaxel (20 mg/m) and the Currently Approved Dose (25 mg/m) in Postdocetaxel Patients With Metastatic Castration-Resistant Prostate Cancer-PROSELICA.卡巴他赛（20mg/m2）与目前批准剂量（25mg/m2）在多西他赛治疗后转移性去势抵抗性前列腺癌患者中的 III 期比较研究-PROSELICA。
J Clin Oncol. 2017 Oct 1;35(28):3198-3206. doi: 10.1200/JCO.2016.72.1076. Epub 2017 Aug 15.
10
Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study.恩杂鲁胺用于未经化疗的转移性去势抵抗性前列腺癌男性患者：3期PREVAIL研究的扩展分析
Eur Urol. 2017 Feb;71(2):151-154. doi: 10.1016/j.eururo.2016.07.032. Epub 2016 Jul 28.